[AstraZeneca invests 200 million yuan to upgrade Wuxi base] September 17th, AstraZeneca announced on September 17 that it will invest nearly 200 million yuan to upgrade the new drug development and supply building of the Wuxi production and supply base to support the process development, production and commercialization of innovative cardiovascular drugs under development and global supply. The project has a construction area of ​​approximately 5,800 square meters and is scheduled to be put into operation in the fourth quarter of 2029. It is expected to have an annual production capacity of 400 million pieces. This investment is expected to promote the Wuxi base to become AstraZeneca's first base in the Asia-Pacific region with global launch and supply capabilities for new drugs. It is also part of AstraZeneca's plan to "invest more than 100 billion yuan in China by 2030". (Interface News reporter Huang Hua)